aSource: IQVIA XPD NBRx by specialty, for the period starting on 3/05/21 through 2/25/22. Includes add-on, switches, and GLP-1–naïve patients. New prescriptions are defined as new-to-brand prescriptions (NBRx) or the number of patients starting a prescription drug who have not previously used the product.
bComposite MACE endpoint in SUSTAIN 6 included: CV death, nonfatal MI, or nonfatal stroke.
cWeight change was a secondary endpoint in clinical trials.
T2D=type 2 diabetes; CVD=cardiovascular disease; MACE=major adverse cardiovascular event; GLP-1 RA=glucagon-like peptide-1 receptor agonist; CV=cardiovascular; ASCVD=atherosclerotic cardiovascular disease; MI=myocardial infarction; HR=hazard ratio.